4.5 Article

Iron Deficiency Anemia in Women Across the Life Span

Journal

JOURNAL OF WOMENS HEALTH
Volume 21, Issue 12, Pages 1282-1289

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/jwh.2012.3713

Keywords

-

Funding

  1. University of Arizona Office of Continuing Medical Education
  2. American Regent, Inc.
  3. Luitpold Pharmaceuticals, Inc.
  4. Society for the Advancement of Blood Management (SABM)
  5. Bayer
  6. Novartis
  7. Novo Nordisk
  8. OrthoBiotech
  9. Pfizer
  10. ZymoGenetics

Ask authors/readers for more resources

Anemia is a global health issue with disproportionately high prevalence in women. In addition to being an independent risk factor for decreased quality of life and increased morbidity and mortality, anemia in women has been linked to unfavorable outcomes of pregnancy and other issues for children born to anemic women. Iron deficiency is the leading cause of anemia in many populations. Guidelines recommend proactive screening for anemia, particularly in the preoperative setting. Once anemia is diagnosed, treatment should be based on etiology (most commonly, iron deficiency followed, in order of prevalence, by inflammation or chronic disease). Iron supplementation (oral and intravenous) offers safe and effective treatment for anemia associated with iron deficiency. Anemia of chronic disease may be more challenging to treat, and attention must be given to the underlying disease, along with use of hematinic agents. Given its enormous impact on the health and well-being of women and the availability of simple and effective treatment options, anemia should never be left unmanaged.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available